Author:
D’Souza Deepak Cyril,Raj Justin,Ganesh Suhas,Goyal Nishant,KL Vidya,Tikka Sai Krishna,Shreekantiah Umesh,Murthy Pratima,Ram Daya,Sharma Priyamvada,Sinha Vinod K,Cortes-Briones Jose
Abstract
AbstractIntroductionCannabis use has been associated with several psychosis outcomes including acute and persistent psychosis termed Cannabis Induced Psychotic Disorder (CIPD). The clinical and cognitive profile, course of CIPD, and the extent to which it is different from psychosis unrelated to cannabis exposure (PsyNoCan) is not clear.MethodsThe acute presentation and short-term (∼4 weeks) course of hospitalized male patients with new onset CIPD were compared prospectively to PsyNoCan using measures of psychosis, depression, mania, memory and other cognitive processes at admission, and after 4 weeks of inpatient hospitalization. A subsample of CIPD patients were followed up after 4-6 months of discharge. Cognitive test performance was benchmarked for comparison in healthy controls and individuals with Cannabis Use Disorder.ResultsCompared to PsyNoCan (n=53), CIPD (n=66) had a significantly lower severity of psychotic symptoms at admission but no differences in mood symptoms. After 4 weeks of hospitalization, the CIPD group had less psychosis. While both groups had significant cognitive deficits at baseline compared to healthy controls, cognitive test performance improved to a greater extent in CIPD. Amongst 16 CIPD cases with longitudinal follow-up data, 10 relapsed with psychosis within 6 months after resuming cannabis use.ConclusionCIPD in males has a distinct presentation and short-term course, characterized by less severe psychosis, and greater resolution of psychopathology and cognitive deficits relative to PsyNoCan. Relapse of cannabis use may predict poorer long-term outcomes with greater psychotic relapses. The longer-term course, prognosis and biology of CIPD, and its presentation in females needs further study.
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. Heterogeneity of schizophrenia;Biol Psychiatry,1975
2. Strategies for Advancing Disease Definition Using Biomarkers and Genetics: The Bipolar and Schizophrenia Network for Intermediate Phenotypes;Biological Psychiatry: Cognitive Neuroscience and Neuroimaging,2017
3. Tikka SK , D’Souza DC . The Association Between Cannabinoids and Psychosis. In: Montoya ID , Weiss SRB , eds. Cannabis Use Disorders. Cham: Springer International Publishing; 2019:127–155.
4. Hindley G , Beck K , Borgan F , et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. The Lancet Psychiatry.
5. Radhakrishnan R , Wilkinson ST , D’Souza DC . Gone to Pot – A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry 2014-May-22 2014;5(54).